FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 703 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR The vaccination of a generation? – That Cancer Conversation December 9, 2021 Study Shows 4 Drugs Better Than 3 for Women with HER2-Positive... June 21, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib March 27, 2026 Dame Deborah James’ incredible legacy: The Bowelbabe Fund announces first funded... April 5, 2023 Load more HOT NEWS As More People with Cancer Use Medical Cannabis, Oncologists Face Questions... T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast... ESMO Gynaecological Cancers Congress 2023 FDA Approves Pembrolizumab for Adjuvant Treatment of Stage IIB or IIC...
